Company Filing History:
Years Active: 2007
Title: The Innovative Contributions of Brian Neil Zeiler in Agglomeration Proteins
Introduction
Brian Neil Zeiler, an inventive mind based in Washington Township, NJ, has made significant advancements in the field of biotechnology. His innovative work primarily focuses on compositions and methods for binding agglomeration proteins, showcasing his dedication to scientific research and development.
Latest Patents
Zeiler holds a patent for "Compositions and methods for binding agglomeration proteins." This patent outlines various amplibody compositions and methods that interact with agglomeration proteins. The compositions consist of DNA or RNA molecules that exhibit affinity for at least one agglomeration protein. Notably, the nucleic acid component can either be naturally or non-naturally occurring, containing twenty or more ribonucleotide bases. The methods described in the patent also involve detecting the presence of agglomeration proteins in a sample matrix, underscoring the practical application of his research.
Career Highlights
Zeiler is currently associated with Oligomerix, Inc., a company that focuses on developing therapies and diagnostics. His role at the company highlights his involvement in real-world applications of his scientific discoveries. Throughout his career, Zeiler has demonstrated a commitment to advancing the understanding of agglomeration proteins and their implications in various biological contexts.
Collaborations
In his professional journey, Zeiler has worked alongside notable colleagues, including Abraham Grossman and Valentine M. Kryukov. These collaborations reflect a shared vision among researchers to push the boundaries of knowledge in the field of biochemistry and biotechnology.
Conclusion
Brian Neil Zeiler's contributions to the study of agglomeration proteins are commendable and represent a significant step forward in biotechnology. His patent demonstrates innovative thinking regarding RNA and DNA interactions, providing essential methods for detection and potential therapeutic applications. As research continues to evolve, Zeiler's work will undoubtedly inspire future innovations in the field.